Mackenzie Financial
NKTR icon

Mackenzie Financial’s Nektar Therapeutics NKTR Stock Holding History

Mackenzie Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,583
Closed -$1.13M – 1775
2025
Q1 		$1.13M Buy
110,583
+79,265
+253% +$1.04M ﹤0.01% 949
2024
Q4 		$437K Buy
31,318
+27,843
+801% +$491K ﹤0.01% 1233
2024
Q3 		$67.8K Buy
3,475
+557
+19% +$10.6K ﹤0.01% 1518
2024
Q2 		$54.3K Sell
2,918
-3,551
-55% -$74.8K ﹤0.01% 1488
2024
Q1 		$90.7K Buy
6,469
+1,467
+29% +$15.4K ﹤0.01% 1432
2023
Q4 		$42.4K Buy
+5,002
New +$37.9K ﹤0.01% 1454
2023
Q2 		– Sell
-796
Closed -$8.39K – 1596
2023
Q1 		$8.39K Hold
796
– – ﹤0.01% 1503
2022
Q4 		$27K Hold
796
– – ﹤0.01% 1387
2022
Q3 		$38K Sell
796
-34
-4% -$2.02K ﹤0.01% 1375
2022
Q2 		$47K Buy
+830
New +$52.4K ﹤0.01% 1400
2019
Q3 		– Sell
-1,539
Closed -$822K – 1072
2019
Q2 		$822K Sell
1,539
-1,221
-44% -$612K ﹤0.01% 778
2019
Q1 		$1.39M Buy
2,760
+2,005
+266% +$1.19M ﹤0.01% 862
2018
Q4 		$372K Sell
755
-269
-26% -$162K ﹤0.01% 986
2018
Q3 		$936K Buy
1,024
+623
+155% +$532K ﹤0.01% 770
2018
Q2 		$294K Buy
401
+128
+47% +$148K ﹤0.01% 894
2018
Q1 		$436K Buy
+273
New +$352K ﹤0.01% 758
2013
Q3 		– Sell
-2,680
Closed -$464K – 652
2013
Q2 		$464K Buy
+2,680
New +$411K ﹤0.01% 589

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mackenzie Financial's NKTR Position: Q2 2025 in Review

Mackenzie Financial sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 110,583 shares — an estimated $1.13M sold.

Mackenzie Financial first reported a position in NKTR in Q2 2013 and held it in 17 quarters. The position peaked at $1.39M in Q1 2019. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Mackenzie Financial reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mackenzie Financial sold 110,583 Nektar Therapeutics shares in Q2 2025, an estimated $1.13M.
  • Mackenzie Financial first reported a position in Nektar Therapeutics in Q2 2013 and held it in 17 quarters.
  • Mackenzie Financial's Nektar Therapeutics position peaked at $1.39M in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.